GlassScriptPhysician profile
Damon J Thomas
NPI 1023100773
$5,360.22
in general payments reported to CMS, 2019-2025
31 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $216 · 2021: $688 · 2022: $923 · 2023: $740 · 2024: $1,120 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Education: $14.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.10 |
| Education | $14.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $971.43 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $917.76 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $632.40 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $476.72 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $377.56 | 2021-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.32 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $208.10 | 2023-2025 | Rexulti |
| Pfizer INC. | $177.21 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $127.80 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $109.26 | 2019-2021 | |
| Mylan Specialty L.P. | $107.67 | 2019-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.41 | 2025 | Caplyta |
| Astellas Pharma US INC | $96.63 | 2019-2025 | Veozah |
| Dexcom, INC. | $92.03 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $79.10 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.43 | 2019-2021 | |
| Biogen, INC. | $63.19 | 2024-2025 | Skyclarys |
| Idorsia Pharmaceuticals US INC | $53.55 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $50.10 | 2024 | Voquezna |
| Lundbeck LLC | $46.24 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $45.57 | 2019-2020 | |
| Amgen INC. | $36.71 | 2024-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.28 | 2022-2024 | Xifaxan |
| Abbvie INC. | $26.03 | 2022 | |
| Alkermes, INC. | $19.46 | 2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $18.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.26 | 2022 | |
| Viatris Specialty LLC | $17.23 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $15.87 | 2023 | |
| Eisai INC. | $11.73 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.